Hapoalim Securities raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $19 from $16. It is reiterating its Buy rating on shares.
In a note to clients, Hapoalim writes, "After the impressive Phase II ovarian and breast...(read more
Below are the top drug delivery stocks on the NYSE and the NASDAQ in terms of cash.
Hospira Inc (NYSE: HSP) had $1.15 billion in total cash for the latest quarter. HSP's total debt stood at $2.24 billion in the same period.
Recently, Nektar Therapeutics (NKTR) announced preliminary results from the first stage of phase II study of its experimental ovarian cancer drug, NKTR-102. It has been...(read more